A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects With Castration-Resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Seviteronel (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; First in man
- Sponsors Innocrin Pharmaceuticals; Viamet Pharmaceuticals
- 28 Feb 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 28 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2018.
- 28 Feb 2018 Status changed from recruiting to active, no longer recruiting.